On the other hand, AnxA1 or AnxA1-related peptides counteract non-alcoholic steatohepatitis [13], as well as atherosclerosis and cardiovascular disease triggered by hyperlipidemia [14–16]. The gene discussed is ANXA1; the disease is metabolic dysfunction-associated steatohepatitis.